Immunovant Will Use $200M Investment to Advance IMVT-1401

Immunovant Will Use $200M Investment to Advance IMVT-1401

301918

Immunovant Will Use $200M Investment to Advance IMVT-1401

Immunovant will use a $200 million strategic investment from Roivant Sciences to advance IMVT-1401, its investigational therapy for myasthenia gravis (MG) and other autoimmune conditions. A pivotal clinical trial testing IMVT-1401 in people with MG is expected to be launched within the next 12 months, according to the company. “We are excited to announce this significant investment by Roivant, which will expedite our development of IMVT-1401 for a wide range of autoimmune disorders,” Pete Salzmann, MD,…

You must be logged in to read/download the full post.